Company profile
Novai
Novai is a disruptive British biotech start-up with an AI supported retinal biomarker for use in glaucoma and AMD clinical trials.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUyNjU3ODI0NWFkaXF6a2N4 | Paper/PDF filed
Published 25 Jun 2026 08:54
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jul 2022 to 30 Jun 2023
Novai Ltd (Novai) is a UK biotech SME with a core project team of Dr John Maddison (Project Lead/CTO), Dr Jonathan Young (Data Scientist) and Professor Francesca Cordeiro (Scientific Lead). Novai is aiming to develop its retinal biomarker, DARC, for earlier disease detection so it can be used to identify and monitor progression in MS patients. This innova...
1 Feb 2021 to 31 Jul 2023
Novai Ltd is developing a highly sensitive diagnostic tool for ophthalmic diseases allowing very early diagnosis, disease monitoring and patient stratification. The solution has already demonstrated powerful prognostic capability, accurately predicting the degree of disease progression in a cohort of glaucoma patients in Phase 1 and Phase 2 clinical trial...
1 Oct 2020 to 31 May 2021
**Public Description** Novai Ltd. is a rapidly growing UK-SME specialising in biotechnology and data science. Novai was founded by Dr John Maddison, Professor Francesca Cordeiro and Aman Khan; the founders have 20 years' experience in the development and management of impactful and clinical projects. There is an unmet need in accelerating and de-risking d...
